GD2-CART01治疗复发或难治性高危神经母细胞瘤
这项学术性1-2期临床试验纳入27例1至25岁复发或难治性高危神经母细胞瘤患者,接受表达诱导型caspase 9自杀基因的自体第三代GD2-CAR T细胞(GD2-CART01)治疗。1期测试3个剂量水平(3、6、10×10^6 CAR阳性T细胞/kg体重),未记录剂量限制性毒性,2期推荐剂量为10×10^6 CAR阳性T细胞/kg。细胞因子释放综合征发生于27例中的20例(74%),其中19/20(95%)为轻度;1例激活自杀基因后GD2-CART01快速清除。17例(63%)有效,其中9例完全缓解、8例部分缓解;推荐剂量组3年总生存率和无事件生存率分别为60%和36%。结论认为GD2-CART01治疗高危神经母细胞瘤可行且安全,自杀基因激活可控制副作用,可能具有持续抗肿瘤效应。
要点
- 27例复发或难治性高危神经母细胞瘤患者接受GD2-CART01,未出现制备失败。
- 1期3个剂量水平未记录剂量限制性毒性,2期推荐剂量为10×10^6 CAR阳性T细胞/kg。
- 细胞因子释放综合征发生于20/27例(74%),19/20例(95%)为轻度;1例激活自杀基因后GD2-CART01快速清除。
核心结论
- GD2-CART01治疗高危神经母细胞瘤可行且安全,治疗相关毒性反应出现,自杀基因激活可控制副作用,GD2-CART01可能具有持续抗肿瘤效应。
研究设计与样本
- 学术性1-2期临床试验,纳入1至25岁复发或难治性高危神经母细胞瘤患者,测试自体第三代GD2-CAR T细胞(表达诱导型caspase 9自杀基因,GD2-CART01)。
- 共27例儿童入组并接受GD2-CART01,其中12例难治性疾病、14例复发性疾病、1例一线治疗结束时完全缓解。
主要发现
- 未观察到GD2-CART01制备失败。
- 1期部分测试3个剂量水平(3、6、10×10^6 CAR阳性T细胞/kg体重),未记录剂量限制性毒性;2期推荐剂量为10×10^6 CAR阳性T细胞/kg。
- 细胞因子释放综合征发生于27例中的20例(74%),20例中19例(95%)为轻度。
- 1例患者自杀基因被激活,GD2-CART01快速清除。
- GD2靶向CAR T细胞在体内扩增,27例中26例在输注后长达30个月可于外周血中检测到(中位持续3个月,范围1至30个月)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunotherapy with chimeric antigen receptor (CAR)-expressing T cells that target the disialoganglioside GD2 expressed on tumor cells may be a therapeutic option for patients with high-risk neuroblastoma. METHODS: In an academic, phase 1-2 clinical trial, we enrolled patients (1 to 25 years of age) with relapsed or refractory, high-risk neuroblastoma in order to test autologous, third-generation GD2-CAR T cells expressing the inducible caspase 9 suicide gene (GD2-CART01). RESULTS: A total of 27 children with heavily pretreated neuroblastoma (12 with refractory disease, 14 with relapsed disease, and 1 with a complete response at the end of first-line therapy) were enrolled and received GD2-CART01. No failure to generate GD2-CART01 was observed. Three dose levels were tested (3-, 6-, and 10×106 CAR-positive T cells per kilogram of body weight) in the phase 1 portion of the trial, and no dose-limiting toxic effects were recorded; the recommended dose for the phase 2 portion of the trial was 10×106 CAR-positive T cells per kilogram. Cytokine release syndrome occurred in 20 of 27 patients (74%) and was mild in 19 of 20 (95%). In 1 patient, the suicide gene was activated, with rapid elimination of GD2-CART01. GD2-targeted CAR T cells expanded in vivo and were detectable in peripheral blood in 26 of 27 patients up to 30 months after infusion (median persistence, 3 months; range, 1 to 30). Seventeen children had a response to the treatment (overall response, 63%); 9 patients had a complete response, and 8 had a partial response. Among the patients who received the recommended dose, the 3-year overall survival and event-free survival were 60% and 36%, respectively. CONCLUSIONS: The use of GD2-CART01 was feasible and safe in treating high-risk neuroblastoma. Treatment-related toxic effects developed, and the activation of the suicide gene controlled side effects. GD2-CART01 may have a sustained antitumor effect. (Funded by the Italian Medicines Agency and others; ClinicalTrials.gov number, NCT03373097.).
引用
- Del Bufalo F, De Angelis B, Caruana I, et al. GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. N Engl J Med. 2023. PMID: 37018492. doi:10.1056/NEJMoa2210859
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。